DARPP-32 Antibody (15): sc-135877

DARPP-32 Antibody (15) is a mouse monoclonal IgG1 light chain antibody that detects DARPP-32 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). DARPP-32, or dopamine and adenosine 3′,5′-monophosphate-regulated phosphoprotein, plays a crucial role in dopaminergic signaling pathways, which are vital for various brain functions, including motor control, cognition, and emotional regulation. DARPP-32 is predominantly located in the cytoplasm of neurons that receive dopaminergic input, where DARPP-32 acts as a key integrator of dopamine signaling. Proper localization of DARPP-32 is essential because DARPP-32 allows for precise modulation of downstream signaling pathways in response to dopamine, influencing neuronal excitability and synaptic plasticity. The phosphorylation state of DARPP-32 can determine DARPP-32′s function as a potent inhibitor of protein phosphatase 1 (PP-1), thereby regulating the balance between phosphorylation and dephosphorylation of various target proteins involved in neurotransmission. DARPP-32′s ability to interact with multiple signaling pathways highlights DARPP-32′s significance in understanding the molecular mechanisms underlying neurological disorders such as schizophrenia and Parkinson′s disease, making anti-DARPP-32 antibody (15) an invaluable tool for researchers studying these complex conditions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DARPP-32 Antibody (15) References:

1. DARPP-32 mediates the actions of multiple drugs of abuse.  |  Svenningsson, P., et al. 2005. AAPS J. 7: E353-60. PMID: 16353915
2. Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.  |  Nishi, A. and Shuto, T. 2017. Expert Opin Ther Targets. 21: 259-272. PMID: 28052701
3. The involvement of DARPP-32 in the pathophysiology of schizophrenia.  |  Wang, H., et al. 2017. Oncotarget. 8: 53791-53803. PMID: 28881851
4. DARPP-32 as a marker for D-1 dopaminoceptive cells in the rat brain: prenatal development and presence in glial elements (tanycytes) in the basal hypothalamus.  |  Hökfelt, T., et al. 1988. Adv Exp Med Biol. 235: 65-82. PMID: 2976255
5. DARPP-32 in the orchestration of responses to positive natural stimuli.  |  Scheggi, S., et al. 2018. J Neurochem. 147: 439-453. PMID: 30043390
6. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.  |  Alam, SK., et al. 2020. Br J Cancer. 123: 819-832. PMID: 32499571
7. cAMP-regulated phosphoproteins DARPP-32, ARPP16/19, and RCS modulate striatal signal transduction through protein kinases and phosphatases.  |  Christensen, KR. and Nairn, AC. 2021. Adv Pharmacol. 90: 39-65. PMID: 33706938
8. DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma.  |  Alam, SK., et al. 2022. Oncogene. 41: 83-98. PMID: 34675407
9. DARPP-32/protein phosphatase 1 regulates Rasgrp2 as a novel component of dopamine D1 receptor signaling in striatum.  |  Kuroiwa, M., et al. 2023. Neurochem Int. 162: 105438. PMID: 36351540
10. DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.  |  Bon, G., et al. 2023. Neoplasia. 45: 100937. PMID: 37769528

The preferred DARPP-32 antibody is DARPP-32 Antibody (H-3): sc-271111.